The question of howmany HoFH patients thereare is key not only to Aegerion, but to Isis Pharmaceuticals, which has its own HoFH drug, Kynamro, awaiting FDA approval.
The key question for Dendreon is howmany doctors and patients are out there who can really be convinced to use Provenge, which extended survival in a clinical trial but is cumbersome to give.